PDS Biotechnology (PDSB) Announces Licensing Agreement for Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to PDS Biotechnology (PDSB) Announces Licensing Agreement for Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute

PDS Biotechnology (PDSB) Misses Q3 EPS by 4c; Reports Cash and Cash Equivalents of $69.7M

November 10, 2021 7:29 AM EST

PDS Biotechnology (NASDAQ: PDSB) reported Q3 EPS of ($0.24), $0.04 worse than the analyst estimate of ($0.20).

For earnings history and earnings-related data on PDS Biotechnology (PDSB) click here.

... More